Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 128

    1.

    Erythropoietin, gadolinium, and nephrogenic fibrosing dermopathy.

    Hellman RN.

    Ann Intern Med. 2007 Feb 6;146(3):229-30; author reply 230. No abstract available. PMID: 17283355 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy.

    Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, Griffin MD, Leung N.

    Ann Intern Med. 2006 Aug 1;145(3):234-5. No abstract available. PMID: 16880475 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.

    Prasad SR, Jagirdar J.

    J Comput Assist Tomogr. 2008 Jan-Feb;32(1):1-3. Review.PMID: 18303280 [PubMed - indexed for MEDLINE]Related articles

    4.

    Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.

    Jamboti J.

    Intern Med J. 2007 Jul;37(7):508-9; author reply 509. No abstract available. PMID: 17547734 [PubMed - indexed for MEDLINE]Related articles

    5.

    Gadolinium and nephrogenic systemic fibrosis: association or causation.

    Kurtkoti J, Snow T, Hiremagalur B.

    Nephrology (Carlton). 2008 Jun;13(3):235-41. Epub 2008 Jan 23. Review.PMID: 18221255 [PubMed - indexed for MEDLINE]Related articles

    6.

    Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients.

    Dharnidharka VR, Wesson SK, Fennell RS.

    Pediatr Nephrol. 2007 Sep;22(9):1395. Epub 2006 Dec 16. No abstract available. PMID: 17180360 [PubMed - indexed for MEDLINE]Related articles

    7.

    Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

    Goveia M, Chan BP, Patel PR.

    J Am Acad Dermatol. 2007 Oct;57(4):725-7. Epub 2007 Aug 8. No abstract available. PMID: 17689832 [PubMed - indexed for MEDLINE]Related articles

    8.

    Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.

    Hamilton-Persaud K, Ezell LD, Macklin JG.

    Nephrol Nurs J. 2007 May-Jun;34(3):283-7; quiz 288. Review.PMID: 17644872 [PubMed - indexed for MEDLINE]Related articles

    9.

    New insights into nephrogenic systemic fibrosis.

    Swaminathan S, Shah SV.

    J Am Soc Nephrol. 2007 Oct;18(10):2636-43. Epub 2007 Sep 12. Review.PMID: 17855637 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Nephrogenic systemic fibrosis, gadolinium, and iron mobilization.

    Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah SV.

    N Engl J Med. 2007 Aug 16;357(7):720-2. No abstract available. PMID: 17699829 [PubMed - indexed for MEDLINE]Related articles

    11.

    Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?

    Bongartz G.

    MAGMA. 2007 Apr;20(2):57-62. Epub 2007 Apr 14. Review.PMID: 17436028 [PubMed - indexed for MEDLINE]Related articles

    12.

    Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy.

    Stratta P, Canavese C, Aime S.

    Curr Med Chem. 2008;15(12):1229-35. Review.PMID: 18473815 [PubMed - indexed for MEDLINE]Related articles

    13.

    Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy.

    Stöllberger C, Finsterer J.

    Nephrol Dial Transplant. 2006 Dec;21(12):3604; author reply 3604-5. No abstract available. PMID: 17105824 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.

    Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA.

    J Am Acad Dermatol. 2007 Jul;57(1):105-11. Epub 2007 Apr 6.PMID: 17412451 [PubMed - indexed for MEDLINE]Related articles

    15.

    Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy).

    Galan A, Cowper SE, Bucala R.

    Curr Opin Rheumatol. 2006 Nov;18(6):614-7. Review.PMID: 17053507 [PubMed - indexed for MEDLINE]Related articles

    16.

    [Risk of using gadolinium in patients with renal insufficiency]

    Greloni G, Rosa Diez G, Hidalgo Parra I, Torre A, García Mónaco R, Algranati S.

    Medicina (B Aires). 2008;68(4):346-7. Spanish. No abstract available. PMID: 18786896 [PubMed - indexed for MEDLINE]Related articles

    17.

    Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.

    Moreno-Romero JA, Segura S, Mascaró JM Jr, Cowper SE, Julià M, Poch E, Botey A, Herrero C.

    Br J Dermatol. 2007 Oct;157(4):783-7. Epub 2007 Jul 11.PMID: 17627792 [PubMed - indexed for MEDLINE]Related articles

    18.

    Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.

    Peak AS, Sheller A.

    Ann Pharmacother. 2007 Sep;41(9):1481-5. Epub 2007 Aug 7. Review.PMID: 17684032 [PubMed - indexed for MEDLINE]Related articles

    19.

    Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.

    Chewning RH, Murphy KJ.

    J Vasc Interv Radiol. 2007 Mar;18(3):331-3. Review. Erratum in: J Vasc Interv Radiol. 2007 Nov;18(11):1463. PMID: 17377176 [PubMed - indexed for MEDLINE]Related articles

    20.

    Nephrogenic fibrosing dermopathy: report of two cases.

    Aires NB, Sotto MN, Nico MM.

    Acta Derm Venereol. 2007;87(6):521-4. Review.PMID: 17989891 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data